Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: A retrospective real world study.

被引：1
|
作者：
Chen, Yang
Dai, Guanghai
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
113
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
    Aoki, Masahiko
    Iwasa, Satoru
    Boku, Narikazu
    GASTRIC CANCER, 2021, 24 (03) : 567 - 576
  • [42] Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
    Masahiko Aoki
    Satoru Iwasa
    Narikazu Boku
    Gastric Cancer, 2021, 24 : 567 - 576
  • [43] HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab
    Kawamoto, Y.
    Yuki, S.
    Meguro, T.
    Hatanaka, K.
    Uebayashi, M.
    Iwanaga, I.
    Nakamura, M.
    Eto, K.
    Okuda, H.
    Abe, M.
    Aonuma, A.
    Abe, N.
    Sato, A.
    Nakatsumi, H.
    Muranaka, T.
    Yagisawa, M.
    Oba, K.
    Sakata, Y.
    Sakamoto, N.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab
    Takahide, Sasaki
    Yasuyuki, Kawamoto
    Satoshi, Yuki
    Takashi, Meguro
    Kazuteru, Hatanaka
    Minoru, Uebayashi
    Ichiro, Iwanaga
    Michio, Nakamura
    Kazunori, Eto
    Hiroyuki, Okuda
    Masakazu, Abe
    Ayane, Oba
    Nobuhiko, Abe
    Atsushi, Sato
    Hiroshi, Nakatsumi
    Kazuaki, Harada
    Tetsuhito, Muranaka
    Masataka, Yagisawa
    Koji, Oba
    Yuh, Sakata
    Yoshito, Komatsu
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] Survival of patients with HER2-positive gastric cancer with introduction of trastuzumab.
    Shitara, Kohei
    Yatabe, Yasushi
    Sugano, Masato
    Matsuo, Keitaro
    Kondo, Chihiro
    Takahari, Daisuke
    Ura, Takashi
    Tajika, Masahiro
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [46] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Mueller, Volkmar
    Clemens, Michael
    Jassem, Jacek
    Al-Sakaff, Nedal
    Auclair, Petra
    Nuesch, Eveline
    Holloway, Debbie
    Shing, Mona
    Bang, Yung-Jue
    BMC CANCER, 2018, 18
  • [47] Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study
    Sang, Die
    Su, Yanfang
    Zhang, Yurong
    Guan, Yanfeng
    Fan, Shanmin
    Zhang, Jintao
    Zheng, Lijun
    Wang, Yanling
    Guo, Ying
    Lei, Zixuan
    Li, Man
    Yuan, Peng
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [48] Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer A Retrospective Analysis
    Park, Joo-Hwan
    Yeo, Ja Hyun
    Kim, Young Saing
    Park, Inkeun
    Ahn, Hee Kyung
    Cho, Eun Kyung
    Shin, Dong Bok
    Yang, Jun-Young
    Kim, Hyung-Sik
    Lee, Woon Kee
    Sym, Sun Jin
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2022, 45 (02): : 61 - 65
  • [49] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Volkmar Müller
    Michael Clemens
    Jacek Jassem
    Nedal Al-Sakaff
    Petra Auclair
    Eveline Nüesch
    Debbie Holloway
    Mona Shing
    Yung-Jue Bang
    BMC Cancer, 18
  • [50] Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer
    Zhifei Li
    Huan Zhao
    Huihui Hu
    Haili Shang
    Yongjing Ren
    Wenhui Qiu
    Hao Su
    Huifang Lyu
    Xiaobing Chen
    Chinese Journal of Cancer Research, 2024, 36 (03) : 306 - 321
12345